Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs
about
Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening MethodologiesInteractions of Monoamine Oxidases with the Antiepileptic Drug Zonisamide: Specificity of Inhibition and Structure of the Human Monoamine Oxidase B ComplexThe ‘gating’ residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognitionMolecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes DrugsInhibitors of MAO-A and MAO-B in Psychiatry and NeurologyKey Targets for Multi-Target Ligands Designed to Combat NeurodegenerationMolecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidasesWhy p-OMe- and p-Cl-β-Methylphenethylamines Display Distinct Activities upon MAO-B BindingBehavioral outcomes of monoamine oxidase deficiency: preclinical and clinical evidence.New small molecules for the treatment of Parkinson's disease.Superpose3D: a local structural comparison program that allows for user-defined structure representations.Catalytic and inhibitor binding properties of zebrafish monoamine oxidase (zMAO): comparisons with human MAO A and MAO BExploration of a Library of 3,4-(Methylenedioxy)aniline-Derived Semicarbazones as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase: Design, Synthesis, and Evaluation.Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.Palladium-catalyzed substitution of (coumarinyl)methyl acetates with C-, N-, and S-nucleophilesInhibition of monoamine oxidase by (E)-styrylisatin analoguesDual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's diseaseComputational Drug Target Screening through Protein Interaction Profiles.Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Safinamide in the treatment of Parkinson's disease.Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential.Monoamine oxidases in development.From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors.Current status of safinamide for the drug portfolio of Parkinson's disease therapy.Safinamide for the treatment of Parkinson's disease.Investigational approaches to therapies for restless legs syndrome.Safinamide for the treatment of Parkinson's disease.Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.Investigational agents in the treatment of Parkinson's disease: focus on safinamide.Through scaffold modification to 3,5-diaryl-4,5-dihydroisoxazoles: new potent and selective inhibitors of monoamine oxidase B.Synthesis, pharmacological study and docking calculations of new benzo[f]coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases.Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A(2A) Receptors for the Treatment of Parkinson's Disease.Assessment of Enzyme Inhibition: A Review with Examples from the Development of Monoamine Oxidase and Cholinesterase Inhibitory Drugs.Design, synthesis, in vitro MAO-B inhibitory evaluation, and computational studies of some 6-nitrobenzothiazole-derived semicarbazones.Design, Synthesis, and Evaluation of 2-Amino-6-nitrobenzothiazole-Derived Hydrazones as MAO Inhibitors: Role of the Methylene Spacer Group.Discovery of 3-Hydroxy-3-phenacyloxindole Analogues of Isatin as Potential Monoamine Oxidase Inhibitors.Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.Multi-Target Screening and Experimental Validation of Natural Products from Selaginella Plants against Alzheimer's Disease.
P2860
Q26745421-91C99BC4-B0AE-4353-A1D6-D72CA02CE817Q27666365-61C22FDD-BF72-458B-AC7B-2E3CEB2C5B69Q27674763-E6EEF2A9-D08F-4BAB-8978-D623F1AD177BQ27676922-086B4CAB-4CA5-487D-9B10-D4E29A601EA0Q28069609-FADA831E-C616-4444-BC48-10931B6B49EAQ28077589-8E94C15E-FBCF-426A-BC85-57E6BA8A3364Q28475810-EF4DE37F-8382-4330-93F7-900813298A0EQ28551848-1CBC4FF7-DC28-4513-8F5B-C5AAC8CC42E1Q30466736-288D8464-8989-4361-B879-8A935288EC73Q33636631-998931CE-B8F3-4220-8C4A-3679757F2411Q33654264-70BDE974-7F98-428F-AE94-C59E4B01C5FFQ34768200-72EAF991-9154-4DE8-9DBA-94FD9FE9C36CQ36004978-22EE7EAC-DEE5-46FC-80BD-87E596D407A9Q36250876-294D3F30-545D-4883-815F-F38844332962Q36281180-0D0F3322-3BB8-4372-AA43-3FBFAE2D63B3Q37218632-F99443AE-B592-45EA-B25B-1B5EBDF24F94Q37358676-DEFE9B07-0FCB-4F9F-A7B7-4073353B22D1Q37414273-8233A494-8D0C-4C67-A0C7-A2F0E42DAADCQ37578490-FCEF4252-D3B2-400B-AFD4-7B7C4F89FEA3Q37779808-5AB4DA8F-21DB-42B2-AC9D-FC86A2BC553BQ37963572-A76347D9-16F2-4189-9790-5C80FCA34102Q38019012-7C7F6561-D08A-4839-838B-F25857A2E55CQ38025300-D6E48834-0D64-4BF6-8BA6-AEE7EB4F77F4Q38040128-EF3090FD-332F-462E-8F68-2E3EBB4BDF89Q38140018-552A1208-C158-4308-B470-AD08EB1EDB51Q38197710-BD87988A-3E14-4D1A-8FA9-230824A448B0Q38202686-D6014AD6-B6FF-4FA3-AE97-FCB20887B097Q38258514-D2FD4233-50FF-4D3A-9A9E-432D5D778DD7Q38640108-3BC6CA2E-FA54-4927-B737-BE550AA9FA85Q38817972-7016D291-DC5C-4593-B5FA-6E5C456686CEQ38836062-09D12937-5B71-44A6-AA21-CD29D05E425CQ39015452-5A95EF2C-150C-4081-8D8E-4BE2A6D7817AQ39229873-F92E9AD8-DA70-4978-ADAF-80822640311DQ39239178-F8F7A912-864A-4920-97B5-8B54867FB613Q39438767-8BBFB531-B783-4FE8-A15B-5D755C3DCA00Q39484040-56315593-8DFD-4101-A125-C2B192010C20Q39664171-50DC727B-FA1E-4255-831E-B1AEE48B3015Q40291145-A9A48E35-B55B-43FF-9837-64FA83924A64Q40621702-193DE65D-E95D-42FA-BCFB-7C9887220120Q41547446-E4AF70AB-794D-4235-8A7C-41D4AC8529DA
P2860
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Structures of human monoamine ...... afinamide and coumarin analogs
@ast
Structures of human monoamine ...... afinamide and coumarin analogs
@en
Structures of human monoamine ...... afinamide and coumarin analogs
@nl
type
label
Structures of human monoamine ...... afinamide and coumarin analogs
@ast
Structures of human monoamine ...... afinamide and coumarin analogs
@en
Structures of human monoamine ...... afinamide and coumarin analogs
@nl
prefLabel
Structures of human monoamine ...... afinamide and coumarin analogs
@ast
Structures of human monoamine ...... afinamide and coumarin analogs
@en
Structures of human monoamine ...... afinamide and coumarin analogs
@nl
P2093
P50
P3181
P356
P1476
Structures of human monoamine ...... afinamide and coumarin analogs
@en
P2093
Angelo Carotti
Carla Caccia
Dale E Edmondson
Patricia Salvati
P304
P3181
P356
10.1021/JM070677Y
P407
P577
2007-11-15T00:00:00Z